BR112018011210A2 - métodos para inibir a conversão de carnitina em trimetilamina (tma) - Google Patents
métodos para inibir a conversão de carnitina em trimetilamina (tma)Info
- Publication number
- BR112018011210A2 BR112018011210A2 BR112018011210A BR112018011210A BR112018011210A2 BR 112018011210 A2 BR112018011210 A2 BR 112018011210A2 BR 112018011210 A BR112018011210 A BR 112018011210A BR 112018011210 A BR112018011210 A BR 112018011210A BR 112018011210 A2 BR112018011210 A2 BR 112018011210A2
- Authority
- BR
- Brazil
- Prior art keywords
- carnitine
- tma
- conversion
- trimethylamine
- inhibit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a invenção fornece um método para inibir a conversão de carnitina em trimetilamina (tma) e reduzir tmao em um indivíduo que compreende administrar ao indivíduo uma ou mais composições que compreendem um composto apresentado na fórmula (i); em que o composto é administrado em uma quantidade eficaz para inibir a conversão de carnitina em tma no indivíduo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562261645P | 2015-12-01 | 2015-12-01 | |
US201562261662P | 2015-12-01 | 2015-12-01 | |
US201662356422P | 2016-06-29 | 2016-06-29 | |
PCT/US2016/064341 WO2017095995A1 (en) | 2015-12-01 | 2016-12-01 | Methods for inhibiting conversion of carnitine to trimethylamine (tma) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018011210A2 true BR112018011210A2 (pt) | 2018-11-21 |
Family
ID=57680518
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018010873-1A BR112018010873A2 (pt) | 2015-12-01 | 2016-12-01 | compostos e métodos para inibir a produção de trimetilamina |
BR112018011216A BR112018011216A2 (pt) | 2015-12-01 | 2016-12-01 | métodos para inibir a conversão de colina em trimetilamina (tma) |
BR112018011210A BR112018011210A2 (pt) | 2015-12-01 | 2016-12-01 | métodos para inibir a conversão de carnitina em trimetilamina (tma) |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018010873-1A BR112018010873A2 (pt) | 2015-12-01 | 2016-12-01 | compostos e métodos para inibir a produção de trimetilamina |
BR112018011216A BR112018011216A2 (pt) | 2015-12-01 | 2016-12-01 | métodos para inibir a conversão de colina em trimetilamina (tma) |
Country Status (9)
Country | Link |
---|---|
US (3) | US10213407B2 (pt) |
EP (3) | EP3383376B1 (pt) |
CN (3) | CN108472267B (pt) |
AU (4) | AU2016365316B2 (pt) |
BR (3) | BR112018010873A2 (pt) |
CA (3) | CA3007081C (pt) |
PL (1) | PL3383376T3 (pt) |
RU (3) | RU2018120183A (pt) |
WO (3) | WO2017095975A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017095975A1 (en) | 2015-12-01 | 2017-06-08 | The Procter & Gamble Company | Compounds and methods for inhibiting production of trimethylamine |
CN109414424A (zh) * | 2016-04-22 | 2019-03-01 | 无锡杰西医药股份有限公司 | 异硫氰酸酯类化合物的应用 |
EP3478276B1 (en) | 2016-06-29 | 2021-10-06 | The Procter & Gamble Company | Methods for inhibiting conversion of choline to trimethylamine (tma) |
WO2018227146A1 (en) * | 2017-06-08 | 2018-12-13 | Allergyintellect, Inc | Vitamin d compounds and methods of using the same |
WO2018236899A1 (en) * | 2017-06-19 | 2018-12-27 | The Cleveland Clinic Foundation | TREATMENT OF A DISEASE AND PROMOTION OF WEIGHT LOSS BY INHIBITING THE TMA / FMO3 / TMAO PATHWAY |
AU2018317401A1 (en) * | 2017-08-14 | 2020-03-05 | Psomagen, Inc. | Targeted drugs associated with trimethylamine and/or trimethylamine-N-oxide |
CN111163763B (zh) | 2017-10-02 | 2023-08-22 | 宝洁公司 | 用于抑制胆碱向三甲胺(tma)的转化的方法 |
CN111163765B (zh) * | 2017-10-02 | 2023-05-09 | 宝洁公司 | 用于抑制胆碱向三甲胺(tma)的转化的方法 |
CN111344016B (zh) * | 2017-10-02 | 2022-04-05 | 宝洁公司 | 用于抑制胆碱向三甲胺(tma)的转化的方法 |
CN108976485B (zh) * | 2018-01-22 | 2020-11-03 | 内蒙古大学 | 一种凝胶多糖与稀土复合的柔性发光薄膜及其制备方法 |
EP3746066A4 (en) * | 2018-02-01 | 2023-05-10 | The Cleveland Clinic Foundation | DISEASE DETECTION AND TREATMENT BASED ON TRIMETHYL-LYSINE LEVELS |
WO2020097152A1 (en) * | 2018-11-06 | 2020-05-14 | The Procter & Gamble Company | Methods for inhibiting conversion of choline to trimethylamine (tma) |
AU2019377820B2 (en) * | 2018-11-06 | 2022-08-11 | The Cleveland Clinic Foundation | Methods for inhibiting conversion of choline to trimethylamine (TMA) |
JP2022510424A (ja) * | 2018-12-06 | 2022-01-26 | センダ バイオサイエンシーズ, インコーポレイテッド | トリメチルアミン産生の阻害剤としての第四級アンモニウム塩 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1242863A (en) * | 1968-05-10 | 1971-08-18 | Pharmacia As | 2,3-DIHYDRO-5H-THIAZOLO[2,3-b]QUINAZOLINES AND PROCESSES FOR THE PREPARATION THEREOF |
US4335141A (en) | 1979-12-26 | 1982-06-15 | Merck & Co., Inc. | 2-Substituted-aminopropene-and propanenitrile antimicrobial and anti-inflammatory agents |
US4874788A (en) | 1985-10-01 | 1989-10-17 | Ethyl Corporation | Quaternary ammonium compounds |
US5547677A (en) | 1994-05-20 | 1996-08-20 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
AU750851B2 (en) | 1998-08-21 | 2002-08-01 | Ciba Specialty Chemicals Holding Inc. | Thermal- and photoinitiated radical polymerization in the presence of an addition fragmentation agent |
WO2002016366A1 (fr) | 2000-08-23 | 2002-02-28 | Itoi Textile Co., Ltd | Chlorophylline de cuivre ou de fer sodee, pate, solution aqueuse de pigment, file de papier et procede de production de celui-ci |
JP4099012B2 (ja) | 2002-07-12 | 2008-06-11 | 富士フイルム株式会社 | 画像形成材料 |
JP4798973B2 (ja) | 2004-08-04 | 2011-10-19 | 丸善製薬株式会社 | 抗菌用組成物 |
US20070199890A1 (en) | 2006-02-27 | 2007-08-30 | Agion Technologies, Inc. | Antimicrobial activated carbon and use thereof |
US8859798B2 (en) | 2006-07-06 | 2014-10-14 | Rutgers, The State University Of New Jersey | Isothiocyanate compounds, pharmaceutical compositions, and uses thereof |
WO2008022298A2 (en) * | 2006-08-17 | 2008-02-21 | The Uab Research Foundation | Immunogenic pcpa polypeptides and uses thereof |
EP2222220B1 (en) | 2007-12-05 | 2016-03-16 | The Cleveland Clinic Foundation | Trimethylamine compounds as risk predictors of cardiovascular disease |
WO2010084661A1 (ja) * | 2009-01-23 | 2010-07-29 | 金印株式会社 | イソチオシアネート類含有組成物、食品、食品素材、医薬品、化粧品および日用品雑貨類 |
US10241093B2 (en) | 2009-05-28 | 2019-03-26 | The Cleveland Clinic Foundation | Trimethylamine-containing compounds for diagnosis and prediction of disease |
CA2790371C (en) * | 2009-05-28 | 2020-09-01 | The Cleveland Clinic Foundation | Trimethylamine-containing compounds for diagnosis and prediction of disease |
WO2010140902A1 (en) | 2009-06-02 | 2010-12-09 | Mark Hampton | Inhibitors of macrophage migration inhibitory factor |
GB0922505D0 (en) * | 2009-12-23 | 2010-02-10 | Plant Bioscience Ltd | Use |
US20120225020A1 (en) | 2011-02-24 | 2012-09-06 | Chekmenev Eduard Y | Unsaturated choline analogs and chemical synthesis thereof |
US9168233B2 (en) | 2012-06-11 | 2015-10-27 | The Cleveland Clinic Foundation | Treatment and prevention of cardiovascular disease and thrombosis |
US20140271923A1 (en) * | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
WO2016054237A2 (en) | 2014-10-03 | 2016-04-07 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad |
WO2017095975A1 (en) | 2015-12-01 | 2017-06-08 | The Procter & Gamble Company | Compounds and methods for inhibiting production of trimethylamine |
EP3478276B1 (en) | 2016-06-29 | 2021-10-06 | The Procter & Gamble Company | Methods for inhibiting conversion of choline to trimethylamine (tma) |
-
2016
- 2016-12-01 WO PCT/US2016/064299 patent/WO2017095975A1/en active Application Filing
- 2016-12-01 RU RU2018120183A patent/RU2018120183A/ru not_active Application Discontinuation
- 2016-12-01 BR BR112018010873-1A patent/BR112018010873A2/pt active Search and Examination
- 2016-12-01 PL PL16819754T patent/PL3383376T3/pl unknown
- 2016-12-01 CA CA3007081A patent/CA3007081C/en active Active
- 2016-12-01 US US15/366,940 patent/US10213407B2/en active Active
- 2016-12-01 CN CN201680068820.1A patent/CN108472267B/zh active Active
- 2016-12-01 BR BR112018011216A patent/BR112018011216A2/pt not_active Application Discontinuation
- 2016-12-01 AU AU2016365316A patent/AU2016365316B2/en active Active
- 2016-12-01 EP EP16819754.9A patent/EP3383376B1/en active Active
- 2016-12-01 AU AU2016365314A patent/AU2016365314A1/en not_active Abandoned
- 2016-12-01 EP EP16823075.3A patent/EP3383378B1/en active Active
- 2016-12-01 WO PCT/US2016/064339 patent/WO2017095993A1/en active Application Filing
- 2016-12-01 CA CA3005760A patent/CA3005760C/en active Active
- 2016-12-01 EP EP16820393.3A patent/EP3383377B1/en active Active
- 2016-12-01 RU RU2018116864A patent/RU2018116864A/ru not_active Application Discontinuation
- 2016-12-01 CA CA3007061A patent/CA3007061C/en active Active
- 2016-12-01 BR BR112018011210A patent/BR112018011210A2/pt not_active Application Discontinuation
- 2016-12-01 US US15/366,877 patent/US10786479B2/en active Active
- 2016-12-01 US US15/366,819 patent/US10780072B2/en active Active
- 2016-12-01 CN CN201680070716.6A patent/CN108601753A/zh active Pending
- 2016-12-01 RU RU2018120189A patent/RU2018120189A/ru not_active Application Discontinuation
- 2016-12-01 WO PCT/US2016/064341 patent/WO2017095995A1/en active Application Filing
- 2016-12-01 AU AU2016362298A patent/AU2016362298B2/en active Active
- 2016-12-01 CN CN201680070816.9A patent/CN108601754A/zh active Pending
-
2019
- 2019-12-13 AU AU2019280094A patent/AU2019280094B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018011210A2 (pt) | métodos para inibir a conversão de carnitina em trimetilamina (tma) | |
BR112018076765A2 (pt) | métodos para inibir a conversão de colina em trimetilamina (tma) | |
BR112018007857A2 (pt) | combinações de gemcabene para o tratamento de doença cardiovascular | |
BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
BR112018003212A2 (pt) | diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3 | |
BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
BR112015022417A2 (pt) | métodos e composições para inibição de proteínas contendo bromodomínio | |
CU20170015A7 (es) | Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il | |
BR112017007072A2 (pt) | compostos de triazolopiridina e métodos para o tratamento de fibrose cística | |
BR112016005881A2 (pt) | composto, composição farmacêutica e uso do composto | |
BR112015016997A2 (pt) | composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama | |
BR112018005194A2 (pt) | processo de composto antifúngico | |
CL2016000378A1 (es) | Composiciones y métodos terapéuticos para la regresión acelerada de placa | |
BR112014017716A8 (pt) | composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol | |
BR112016022593A2 (pt) | composições e métodos para modular a expressão do fator b do complemento | |
BR112017006705A2 (pt) | inibidores de biossíntese de sulfato de heparan para o tratamento de doenças | |
UY36014A (es) | ?derivado de pirazol amida, composición farmacéutica y método para tratar o prevenir enfermedades autoinmunes, inflamatorias, metabólicas o cancerosas?. | |
BR112016021011A8 (pt) | composição tópica e usos de um composto | |
BR112015029987A8 (pt) | Beta-caseína a2 e a prevenção de inflamação do intestino | |
BR112018016032A2 (pt) | composto, composição farmacêutica e método para melhorar um distúrbio | |
BR112015022092A2 (pt) | derivado de di-hidropiridazina-3,5-diona | |
BR112016007462A2 (pt) | fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite | |
BR112015020222A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
BR112016024238A2 (pt) | uso de composições aquosas de redução de desvio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |